Tagarafdeg

N/A

Report date: 2025/12/25 15:59:36
NME

Base Information

Drug NameTagarafdeg
Drug Alias NameCFT-1946CFT1946
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionB-raf V600 mutant degraders
TargetsB-raf V600 mutant
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesC4 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdC4 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A